The US Food and Drug Administration approved two treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for treating sickle cell disease (SCD) in patients 12 years and older. This video highlights the Casgevy treatment option. Treatment of SCD typically is lifelong and has multiple aspects ranging from managing symptoms and vasoocclusive episodes, preventing infections, pa!n control, and even blood transfusions. Before this new development, a “bone marrow transplant”